
    
      A phase I/II, open-label, multicentre study to investigate the safety, tolerability,
      pharmacokinetics and anti-tumour activity of AZD4205 as monotherapy or in combination with
      Osimertinib in patients with EGFR mutant advanced stage non-small cell lung cancer (NSCLC).
      This study includes dose escalation part and dose expansion part.
    
  